Fatima Gulzar
1 min read
In This Article:
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has agreed to pay Roche $36 million to resolve a patent infringement lawsuit over Tandem's t:slim X2 insulin pump.
A hospital room with a patient using a medical device to administer insulin.
The deal settles all pending and prospective litigation about two European patents that Roche filed in December 2023, EP 2 196 231 B1 and EP 1 970 677 B1. Over the next four years, Tandem Diabetes Care, Inc. (NASDAQ:TNDM) will pay the remaining $28 million in four equal annual installments after making an initial payment of $8 million.
Both businesses have signed a cross-license agreement as part of the settlement, which will be in place for ten years and grant each other non-exclusive, non-sublicensable, non-royalty-bearing, and irrevocable rights for patents of insulin delivery systems.
This action ends all ongoing legal proceedings under the Unified Patent Court in France and Germany, including infringement, revocation, and non-infringement declarations.
Tandem Diabetes Care, Inc. (NASDAQ:TNDM)'s t:slim X2 pump will remain commercially available due to the agreement, which also lowers both companies' future legal risk.
While we acknowledge the potential of TNDM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TNDM and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.
Disclosure. None.
